- Home
- SYNX vs APLM Comparison
SYNX vs APLM Comparison
Compare SYNX & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYNX
- APLM
- Stock Information
- Founded
- SYNX 2005
- APLM 2016
- Country
- SYNX Israel
- APLM United States
- Employees
- SYNX N/A
- APLM N/A
- Industry
- SYNX
- APLM Blank Checks
- Sector
- SYNX
- APLM Finance
- Exchange
- SYNX Nasdaq
- APLM Nasdaq
- Market Cap
- SYNX 11.4M
- APLM 6.9M
- IPO Year
- SYNX 2024
- APLM N/A
- Fundamental
- Price
- SYNX $1.67
- APLM $5.80
- Analyst Decision
- SYNX
- APLM
- Analyst Count
- SYNX 0
- APLM 0
- Target Price
- SYNX N/A
- APLM N/A
- AVG Volume (30 Days)
- SYNX 134.0K
- APLM 8.0K
- Earning Date
- SYNX 05-14-2025
- APLM 08-13-2025
- Dividend Yield
- SYNX N/A
- APLM N/A
- EPS Growth
- SYNX N/A
- APLM N/A
- EPS
- SYNX N/A
- APLM N/A
- Revenue
- SYNX $9,094,000.00
- APLM $198,000.00
- Revenue This Year
- SYNX $32.35
- APLM $415.15
- Revenue Next Year
- SYNX N/A
- APLM N/A
- P/E Ratio
- SYNX N/A
- APLM N/A
- Revenue Growth
- SYNX 19.14
- APLM N/A
- 52 Week Low
- SYNX $1.56
- APLM $4.47
- 52 Week High
- SYNX $6.49
- APLM $35.98
- Technical
- Relative Strength Index (RSI)
- SYNX 44.20
- APLM 42.59
- Support Level
- SYNX $1.61
- APLM $6.04
- Resistance Level
- SYNX $1.76
- APLM $6.56
- Average True Range (ATR)
- SYNX 0.15
- APLM 0.53
- MACD
- SYNX -0.01
- APLM -0.04
- Stochastic Oscillator
- SYNX 15.28
- APLM 20.49
About SYNX Silynxcom Ltd.
Silynxcom Ltd is engaged in developing, manufacturing, marketing, and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat proved. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, markets, and sell push-to-talk devices, communication controllers, and communication device cables and connectors.
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.